NXTC NextCure, Inc.
6.780USD+3.35%Mkt Cap: 31.03M $P/E: —1d ago
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fu…
Industry Peers
Biotechnology$127.47BUSDP/E 29.3
$78.65BUSD
$76.14BUSDP/E 18.3
$51.48BUSDP/E 31.2
$48.23BUSDP/E 31.4
$41.82BUSDP/E 17.8
$40.32BUSD
$39.83BUSDP/E 62.6
$32.48BUSDP/E 29.9
$30.04BUSDP/E 37.9
$24.71BUSD
$23.13BUSD
$22.85BUSDP/E 14.4
$22.17BUSDP/E 28.4
$21.94BUSD
$21.10BUSDP/E 29.1
$14.65BUSDP/E 17.1
$14.62BUSDP/E 18.6
$14.44BUSDP/E 15.2
$13.70BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
Sector Update: Healthcare Stocks Fall Late Afternoon Healthcare stocks fell late Tuesday afternoon with the NYSE Healthcare Index declining 1.7% and the | ||
 Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde. | ||